OBJECTIVES: To describe the prevalence and risk factors of poor CD4 count rise despite a good virological response on highly active antiretroviral treatment (HAART). METHODS: The patients from the EuroSIDA study who started HAART with a baseline CD4 count of <350 cells/microL and where all viral load (pVL) measures remained below 500 HIV-1 RNA copies/mL between 6 and 12 months after the start of HAART were included. The risk factors for poor CD4 count rise were analyzed by multiple regression. RESULTS: Seven hundred and eighty patients were included. A low CD4 count response was observed in 225 patients (29%). The risk factors for this condition were older age, lower CD4 count at baseline, higher increase from the nadir to baseline CD4 count and lower pVL at baseline. Patients taking > or =one drug from each of the three antiviral classes were more likely to have a good CD4 response but a minority of the study participants was taking this treatment regimen (3.1%) and the confidence interval was large. CONCLUSIONS: A poor immune reconstitution despite a good virological control is frequent after initiation of HAART among patients with a baseline CD4 count of <350 cells/microL. The underlying mechanisms leading to this condition seems mainly driven by the age and the baseline immunological and virological status of the patients.
OBJECTIVES: To describe the prevalence and risk factors of poor CD4 count rise despite a good virological response on highly active antiretroviral treatment (HAART). METHODS: The patients from the EuroSIDA study who started HAART with a baseline CD4 count of <350 cells/microL and where all viral load (pVL) measures remained below 500 HIV-1 RNA copies/mL between 6 and 12 months after the start of HAART were included. The risk factors for poor CD4 count rise were analyzed by multiple regression. RESULTS: Seven hundred and eighty patients were included. A low CD4 count response was observed in 225 patients (29%). The risk factors for this condition were older age, lower CD4 count at baseline, higher increase from the nadir to baseline CD4 count and lower pVL at baseline. Patients taking > or =one drug from each of the three antiviral classes were more likely to have a good CD4 response but a minority of the study participants was taking this treatment regimen (3.1%) and the confidence interval was large. CONCLUSIONS: A poor immune reconstitution despite a good virological control is frequent after initiation of HAART among patients with a baseline CD4 count of <350 cells/microL. The underlying mechanisms leading to this condition seems mainly driven by the age and the baseline immunological and virological status of the patients.
Authors: Ronald J Ellis; Debralee Rosario; David B Clifford; Justin C McArthur; David Simpson; Terry Alexander; Benjamin B Gelman; Florin Vaida; Ann Collier; Christina M Marra; Beau Ances; J Hampton Atkinson; Robert H Dworkin; Susan Morgello; Igor Grant Journal: Arch Neurol Date: 2010-05
Authors: Nadejda Beliakova-Bethell; Sonia Jain; Christopher H Woelk; Mallory D Witt; Xiaoying Sun; Steven M Lada; Celsa A Spina; Miguel Goicoechea; Steffney E Rought; Richard Haubrich; Michael P Dubé Journal: Antiviral Res Date: 2014-04-24 Impact factor: 5.970
Authors: Eric Balestre; Serge P Eholié; Amani Lokossue; Papa Salif Sow; Man Charurat; Albert Minga; Joseph Drabo; François Dabis; Didier K Ekouevi; Rodolphe Thiébaut Journal: AIDS Date: 2012-05-15 Impact factor: 4.177
Authors: Damalie Nakanjako; Agnes N Kiragga; Beverly S Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Lameck Diero; Patrick Oyaro; Emanuel Lugina; John C Ssali; Andrew Kambugu; Philippa Easterbrook Journal: AIDS Date: 2016-07-31 Impact factor: 4.177
Authors: Daniel Merenstein; Yang Yang; Michael F Schneider; Lakshmi Goparaju; Kathleen Weber; Anjali Sharma; Alexandra M Levine; Gerald B Sharp; Monica Gandhi; Chenglong Liu Journal: Altern Ther Health Med Date: 2008 Sep-Oct Impact factor: 1.305
Authors: Vanessa Pirrone; David J Libon; Christian Sell; Chad A Lerner; Michael R Nonnemacher; Brian Wigdahl Journal: Future Virol Date: 2013-01 Impact factor: 1.831